US 12,433,876 B2
Septin inhibitors for treatment of cancers
Rakesh K. Singh, Barrington, RI (US); Kyu K. Kim, Rochester, NY (US); Rachael Turner, Mendon, NY (US); and Richard G. Moore, Victor, NY (US)
Assigned to UNIVERSITY OF ROCHESTER, Rochester, NY (US)
Appl. No. 17/637,953
Filed by UNIVERSITY OF ROCHESTER, Rochester, NY (US)
PCT Filed Aug. 31, 2020, PCT No. PCT/US2020/048712
§ 371(c)(1), (2) Date Feb. 24, 2022,
PCT Pub. No. WO2021/042022, PCT Pub. Date Mar. 4, 2021.
Claims priority of provisional application 62/894,424, filed on Aug. 30, 2019.
Prior Publication US 2022/0280491 A1, Sep. 8, 2022
Int. Cl. A61P 35/00 (2006.01); A61K 31/337 (2006.01); A61K 31/44 (2006.01); A61K 31/4439 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); A61K 39/395 (2006.01); C07D 213/75 (2006.01); C07D 239/42 (2006.01); C07D 401/12 (2006.01)
CPC A61K 31/44 (2013.01) [A61K 31/337 (2013.01); A61K 31/4439 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 39/3955 (2013.01); A61P 35/00 (2018.01); C07D 213/75 (2013.01); C07D 239/42 (2013.01); C07D 401/12 (2013.01)] 7 Claims
 
1. A compound
selected from

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.